The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction.
Young
F E
FE
Office of Health Affairs, Food and Drug Administration, Rockville, Md. 20857.
Nightingale
S L
SL
Temple
R A
RA
D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000139:chemically induced / Q000453:epidemiology; D004311:Double-Blind Method; D004348:Drug Labeling; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control*; D010820:Physicians; D011897:Random Allocation; D012107:Research Design; D012307:Risk Factors; D014481:United States; D014486:United States Food and Drug Administration
D001241:Aspirin